Live Breaking News & Updates on Kishor bhatia

Stay informed with the latest breaking news from Kishor bhatia on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Kishor bhatia and stay connected to the pulse of your community

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th with the first webinar on the increasing prevalence of non-small cell lung cancer in...

United-states , Riyadh , Ar-riya- , Saudi-arabia , Kishor-bhatia , Tesaro-glaxosmithkline , Igor-astsaturov , Paulf-engstrom , Reggie-ewesuedo , Care-at-fox-chase-cancer-center , Department-of-hematology-oncology , Ohio-state-university

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.

The...

Kishor-bhatia , Linkedin , Securities-exchange , Nasdaq , Bielefeld-university , Lantern-pharma-inc , Exchange-commission-on , Lantern-pharma , Business-wire , Chief-scientific-officer , Securities-act

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers – IT Business Net

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

Dallas , Texas , United-states , Kishor-bhatia , Securities-exchange , Exchange-commission-on , Nasdaq , Linkedin , Bielefeld-university , Lantern-pharma-inc , Lantern-pharma , Chief-scientific-officer

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Can

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being furthe...

Kishor-bhatia , Lantern-pharma-inc , Linkedin , Nasdaq , Bielefeld-university , Exchange-commission-on , Securities-exchange , Lantern-pharma , Chief-scientific-officer , Securities-act , Securities-exchange-act

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

DALLAS--(BUSINESS WIRE)--Nov 8, 2023--

Bengaluru , Karnataka , India , South-korea , Canada , Japan , Vancouver , British-columbia , Taiwan , Texas , United-states , Boston

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's Lymphomas

Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options.

Publication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin's lymphoma (NHL) with immediate patient needs.

Lantern is anticipating filing the IND application with the FDA and initiating a first-in-human Phase 1 trial for LP-284 in NHL, including MCL, during the second half of 2023.

Kishor-bhatia , Securities-exchange , Lantern-pharma-inc , Starlight-therapeutics-inc , Exchange-commission-on , Nasdaq , Lantern-pharma , Business-wire , Panna-sharma , Chief-scientific , Publication-highlights , Triple-hit-lymphoma

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

Neha-biyani , Jianli-zhou , Elizabeth-thacker , Sandeep-dave , Kishor-bhatia , Umesh-kathad , Aditya-kulkarni , Megan-craig , Lantern-pharma-inc , Duke-university , Drew-sturtevant , Cassie-love

New drug LP-284 targets non-Hodgkin's lymphoma and DNA damage repair deficiency

New drug LP-284 targets non-Hodgkin's lymphoma and DNA damage repair deficiency
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Elizabeth-thacker , Neha-biyani , Sandeep-dave , Aditya-kulkarni , Kishor-bhatia , Jianli-zhou , Umesh-kathad , Lantern-pharma-inc , Duke-university , Oncotarget-volume , Drew-sturtevant , Cassie-love

Lantern Pharma (LTRN) Leverages RADR to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

Lantern Pharma (LTRN) Leverages RADR to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Munich , Bayern , Germany , Norbert-sewald , Kishor-bhatia , Nicole-leber , Bioorganic-chemistry-at-bielefeld-university-in , Linkedin , Twitter , Bielefeld-university , Technical-university-of-munich

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and...

Dallas , Texas , United-states , Michigan , Berlin , Germany , Matthias-holdhoff , Mattias-holdhoff , John-laterra , Kishor-bhatia , Freie-universit , Johns-hopkins